EPO Patents = 2

Trademarks = 1

Forward Citations = 1

Loading Chart...

4 inventors (with patents filed for the assignee):

Tyler D Ames (3 out of 3 patents)

Wayne Douglas Luke (3 out of 22 patents)

Matthew Price (2 out of 3 patents)

4. Steffen Jost (2 out of 2 patents)

5 patents: Sort by Forward Citations

1. 11439619 - Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof (2022-09-13),

2. 11154529 - Phosphaplatin liquid formulations (2021-10-26),

3. 10668080 - Phosphaplatin compounds as therapeutic agents for treatment of bone or blood cancers (2020-06-02),

4. 8859796 - Synthetic and purification methods for phosphaplatin compounds and uses thereof (2014-10-14),

5. 8846964 - Synthetic method for phosphaplatin compounds (2014-09-30),

Phosplatin Therapeutics Inc. is a biopharmaceutical company focused on developing innovative cancer therapies. Our lead drug candidate, PTX-003, is a novel platinum-based compound that has shown promising results in preclinical studies. We are committed to advancing PTX-003 through clinical trials to bring much-needed treatment options to patients with cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

5 Patents

#1,106 in New York, NY

#2,991 in New York

#50,234 in US

New York, NY, United States of America

Phosplatin Therapeutics Inc.

Forward Citations = 1

4 inventors:

Tyler D Ames (3 out of 3 patents)

Wayne Douglas Luke (3 out of 22 patents)

Matthew Price (2 out of 3 patents)

4. Steffen Jost (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com

2 patents (EPO):

Please report any incorrect information to support@idiyas.com